These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7063525)

  • 21. Impact of affective illness on gene expression: implications for early and long-term prophylaxis.
    Post RM
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():452A-453A. PubMed ID: 1498913
    [No Abstract]   [Full Text] [Related]  

  • 22. Mood disorders.
    Am Fam Physician; 1984 Dec; 30(6):99, 102. PubMed ID: 6507233
    [No Abstract]   [Full Text] [Related]  

  • 23. Effectiveness of lithium in schizophrenia: do we really have an answer?
    Atre-Vaidya N; Taylor MA
    J Clin Psychiatry; 1989 May; 50(5):170-3. PubMed ID: 2654127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autosomal recessive inheritance of affective disorders in families of responders to lithium prophylaxis?
    Alda M; Grof E; Cavazzoni P; Duffy A; Martin R; Ravindran L; Grof P
    J Affect Disord; 1997 Jul; 44(2-3):153-7. PubMed ID: 9241575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants.
    Serretti A; Lorenzi C; Lilli R; Mandelli L; Pirovano A; Smeraldi E
    Am J Med Genet; 2002 May; 114(4):370-9. PubMed ID: 11992559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prophylactic long-term therapy of affective disorders with lithium, valproic acid and carbamazepine--effectiveness and cost-effectiveness].
    Roick C; Ahrens B; Becker T
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S32-40. PubMed ID: 11533905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lithium.
    DePaulo JR
    Psychiatr Clin North Am; 1984 Sep; 7(3):587-99. PubMed ID: 6384961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Affective disorders & "chemical dependence": lithium for alcohol and drug addiction? A clinical note.
    Flemenbaum A
    Dis Nerv Syst; 1974 Jun; 35(6):281-5. PubMed ID: 17894301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of action in the prevention of recurrent mood disorders.
    Baumann B; Krell D; Dobrowolny H; Bielau H
    Pharmacopsychiatry; 2004 Nov; 37 Suppl 2():S157-64. PubMed ID: 15546069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consensus development summaries. Mood disorders: pharmacologic prevention of recurrences. National Institutes of Health.
    Conn Med; 1985 Mar; 49(3):157-63. PubMed ID: 3987266
    [No Abstract]   [Full Text] [Related]  

  • 31. [Prophylactic treatment of mood disorders: cost effectiveness analysis comparing lithium and carbamazepine].
    Dardennes R; Lafuma A; Watkins S
    Encephale; 1999; 25(5):391-400. PubMed ID: 10598301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic lithium treatment: treatment response, and patient attitudes toward illness and treatment.
    Schmidt S; Ludwig W; Seibold S; Greil W
    Pharmacopsychiatry; 1988 Nov; 21(6):274-5. PubMed ID: 3244750
    [No Abstract]   [Full Text] [Related]  

  • 33. [Follow-up evaluation of the prophylactic effect of lithium carbonate in cyclothymia].
    Strzelecka I
    Psychiatr Pol; 1980; 14(4):421-2. PubMed ID: 7003633
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical significance of the erythro-plasmatic ratio of lithium (author's transl)].
    Braccini T; Darcourt G; Corti H; Lapalus P; Lavagna J; Myquel M
    Acta Psychiatr Belg; 1980; 80(4):413-9. PubMed ID: 6116378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mood disorders: pharmacologic prevention of recurrences. A National Institutes of Health consensus report synopsis.
    Hull RH
    Indiana Med; 1985 Jan; 78(1):36-7. PubMed ID: 3968418
    [No Abstract]   [Full Text] [Related]  

  • 36. Role of hereditary, clinical and pharmacokinetic factors for the prediction of lithium prophylactic effect. WHO Collaborative Study.
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(1-2):iii-vii. PubMed ID: 2501824
    [No Abstract]   [Full Text] [Related]  

  • 37. How effective is long-term lithium prophylaxis?
    Vestergaard P
    Acta Psychiatr Scand; 2000 May; 101(5):341-2. PubMed ID: 10823291
    [No Abstract]   [Full Text] [Related]  

  • 38. Quality of interepisodic periods in patients with affective disorders under long-term lithium treatment.
    Volk J; Müller-Oerlinghausen B
    Pharmacopsychiatry; 1988 Nov; 21(6):426-7. PubMed ID: 3244784
    [No Abstract]   [Full Text] [Related]  

  • 39. Prediction of lithium maintenance doses using a single point prediction protocol.
    Perry PJ; Prince RA; Alexander B; Dunner FJ
    J Clin Psychopharmacol; 1983 Feb; 3(1):13-7. PubMed ID: 6833518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of action of lithium in affective disorders: a status report.
    Waldmeier PC
    Pharmacol Toxicol; 1990; 66 Suppl 3():121-32. PubMed ID: 2179927
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.